Papapostolou, I.; Sereti, E.; Chatira, S.; Sakellaridis, N.; Fytas, G.; Zoidis, G.; Dimas, K.
Novel 1-(2-Aryl-2-adamantyl)piperazine Derivatives Exhibit In Vitro Anticancer Activity Across Various Human Cancer Cell Lines, with Selective Efficacy Against Melanoma. Medicina 2025, 61, 1731.
https://doi.org/10.3390/medicina61101731
AMA Style
Papapostolou I, Sereti E, Chatira S, Sakellaridis N, Fytas G, Zoidis G, Dimas K.
Novel 1-(2-Aryl-2-adamantyl)piperazine Derivatives Exhibit In Vitro Anticancer Activity Across Various Human Cancer Cell Lines, with Selective Efficacy Against Melanoma. Medicina. 2025; 61(10):1731.
https://doi.org/10.3390/medicina61101731
Chicago/Turabian Style
Papapostolou, Irida, Evangelia Sereti, Stavroula Chatira, Nikos Sakellaridis, George Fytas, Grigoris Zoidis, and Konstantinos Dimas.
2025. "Novel 1-(2-Aryl-2-adamantyl)piperazine Derivatives Exhibit In Vitro Anticancer Activity Across Various Human Cancer Cell Lines, with Selective Efficacy Against Melanoma" Medicina 61, no. 10: 1731.
https://doi.org/10.3390/medicina61101731
APA Style
Papapostolou, I., Sereti, E., Chatira, S., Sakellaridis, N., Fytas, G., Zoidis, G., & Dimas, K.
(2025). Novel 1-(2-Aryl-2-adamantyl)piperazine Derivatives Exhibit In Vitro Anticancer Activity Across Various Human Cancer Cell Lines, with Selective Efficacy Against Melanoma. Medicina, 61(10), 1731.
https://doi.org/10.3390/medicina61101731
